{"id":3879,"date":"2025-05-15T18:21:45","date_gmt":"2025-05-15T18:21:45","guid":{"rendered":"\/?p=3879"},"modified":"2025-05-15T18:21:45","modified_gmt":"2025-05-15T18:21:45","slug":"sparx-biopharmaceutical-corp-announces-research-agreement-with-mitsubishi-tanabe-pharma-america-to-advance-novel-antibody-drug-conjugates","status":"publish","type":"post","link":"\/?p=3879","title":{"rendered":"SparX Biopharmaceutical Corp Announces Research Agreement with Mitsubishi Tanabe Pharma America to Advance Novel Antibody-Drug Conjugates"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" loading=\"lazy\" width=\"1024\" height=\"683\" src=\"http:\/\/sparxbio.com\/app\/uploads\/2025\/05\/WechatIMG146-1024x683.jpg\" alt=\"\" class=\"wp-image-3880\" srcset=\"\/app\/uploads\/2025\/05\/WechatIMG146-1024x683.jpg 1024w, \/app\/uploads\/2025\/05\/WechatIMG146-300x200.jpg 300w, \/app\/uploads\/2025\/05\/WechatIMG146-768x512.jpg 768w, \/app\/uploads\/2025\/05\/WechatIMG146.jpg 1536w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Chicago, March 31, 2025 \/PRNewswire\/ \u2013 SparX Biopharmaceutical Corp (\u201cSparX\u201d), a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today announced the signing of a research agreement with Mitsubishi Tanabe Pharma America, Inc. (MTPA). This collaboration aims to advance an innovative ADC program: a conceptually novel immune cell target-based ADC.<\/p>\n\n\n\n<p>The research with MTPA will focus on an ADC against a first-in-class immune cell target, with the potential to serve as a universal tumor-targeting strategy across multiple cancer types.&nbsp;<\/p>\n\n\n\n<p>\u201cThis collaboration marks significant milestone for SparX, reflecting the strength of our novel target discovery capabilities\u201d said Gui-Dong Zhu, Ph.D., Founder and CEO of SparX Biopharmaceutical Corp. \u201cWe are excited to work alongside MTPA to bring transformative ADC therapies to patients worldwide.\u201d<\/p>\n\n\n\n<p><strong>About SparX Biopharmaceutical Corp<\/strong><\/p>\n\n\n\n<p>SparX Biopharmaceutical Corp is a research-driven, development-stage biopharmaceutical innovator dedicated to advancing nanobody-based therapeutics through scientific excellence and global collaboration. Guided by its mission to deliver next-generation treatments to patients worldwide, SparX integrates cutting-edge AI and machine learning technologies to decode complex biological systems. The company\u2019s drug discovery engine is powered by robust pharmacological modeling, advanced in vitro and in vivo studies, and a proprietary antibody optimization platform, SAILING\u2122. SparX\u2019s core focus lies in bifunctional and biparatopic ADCs, empowered by its breakthrough Nab2-ADC technology. With in-house cGMP manufacturing capabilities, SparX is rapidly emerging as a fully integrated and self-sustaining biopharmaceutical enterprise.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chicago, March 31, 2025 \/PRNewswire\/ \u2013 SparX Biopharmaceutical Corp (\u201cSparX\u201d), a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today announced the signing of a research agreement with Mitsubishi Tanabe Pharma America, Inc. (MTPA). This collaboration aims to advance an innovative ADC program: a conceptually novel immune cell target-based ADC. The research with MTPA [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3880,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[40],"tags":[],"_links":{"self":[{"href":"\/index.php?rest_route=\/wp\/v2\/posts\/3879"}],"collection":[{"href":"\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3879"}],"version-history":[{"count":2,"href":"\/index.php?rest_route=\/wp\/v2\/posts\/3879\/revisions"}],"predecessor-version":[{"id":3886,"href":"\/index.php?rest_route=\/wp\/v2\/posts\/3879\/revisions\/3886"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/index.php?rest_route=\/wp\/v2\/media\/3880"}],"wp:attachment":[{"href":"\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3879"},{"taxonomy":"post_tag","embeddable":true,"href":"\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}